Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Battelle and Nanotherapeutics form alliance on medical countermeasures

April 6, 2017

SRI International receives FDA clearance to evaluate novel oral formulation of Zn-DTPA

April 3, 2017

BARDA elects not to exercise options for AEOL-10150 development for ARS and DEARE

March 28, 2017

Opiant receives FDA feedback on development of OPNT-002 for alcohol use disorder

March 2, 2017

Aeolus Pharmaceuticals starts phase I study of new formulation of AEOL-10150

Feb. 23, 2017

FDA issues complete response letter for Amphastar's intranasal naloxone

Feb. 23, 2017

Adapt Pharma applies for E.U. approval of naloxone HCl nasal spray

Feb. 22, 2017

Amygdala Neurosciences acquires ALDH2 inhibitor from Gilead

Feb. 17, 2017

Chrysalis Biotherapeutics begins contract with NIAID for TP-508 as nuclear countermeasure

Feb. 9, 2017

GSK-598809 restores reward deficits in substance dependence

Jan. 18, 2017

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...